Ramesh Ramalingam
☆    

India,
2018-10-18 05:16

Posting: # 19463
Views: 490
 

 Theophylline ER 450 mg study design [Design Issues]

Dear Members,

Based on literature reference, Theophylline is a narrow therapeutic index drug. As per USFDA recommendation if the drugs falls under narrow therapeutic index, the BE study should be a fully replicated crossover design in order to:
• Scale bioequivalence limits to the variability of the reference product; and
• Compare test and reference products within-subject variability.

But respective molecule OGD (which was issued on 2010) Draft guidelines recommending two-way cross-over study design.

Could you please suggest the study design whether it should be two-period, two-way crossover design or four period, fully replicated design.


Regards,
Ramesh
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,404 posts in 4,122 threads, 1,323 registered users;
online 7 (1 registered, 6 guests [including 5 identified bots]).
Forum time (Europe/Vienna): 17:09 UTC

Those people who think they know everything
are a great annoyance to those of us who do.    Isaac Asimov

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5